The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients
- 98 Downloads
To evaluate the relationship between serum Anti-Müllerian hormone (AMH) level and body mass index (BMI) in infertile patients.
Medical records of patients with infertility evaluated between January 2013 and February 2018 in the Reproductive Medicine Department of a private hospital were reviewed. Patients with the following criteria were excluded from the study: polycystic ovary syndrome, primary ovarian insufficiency, AMH values > 10 ng/mL, current oral contraceptive users and previous ovarian surgery or endometriosis, and anovulation of other causes, except decreased ovarian reserve.
A total of 2204 infertile patients were included (mean age 34.58 ± 4.3 years, mean BMI 22.35 ± 3.6 kg/m2, and mean serum AMH 2.44 ± 2.17 ng/ml). In the entire group of patients, serum AMH level was positively correlated with BMI after adjustment for age (beta = 0.059, p < 0.005). When the association between serum AMH level and BMI was analysed in subgroups of patients, after adjustment for age, we found a positive correlation between the two parameters in patients ≤ 35 years old (< 0.05), of normal weight (p < 0.05) and with normal ovarian reserve (p < 0.05). After adjustment for age, BMI ≥ 25 kg/m2 was significantly associated with higher AMH values in comparison to normal weight patients.
In infertile patients, AMH is positively correlated with BMI, especially in patients younger than 35 years, of normal weight and with normal ovarian reserve. Moreover, the presence of mild excess adiposity seems to be associated with higher AMH values. Our data contradict the previous studies showing a negative impact of excess adiposity on AMH serum levels.
KeywordsAnti-Müllerian hormone Body mass index Infertility Obesity Adiposity
We are grateful to all of the staff working in the Maternal-foetal and Reproductive Medicine Department of Medlife
Compliance with ethical standards
Conflict of interest
D.A. has received travel grants from Merck, Merck Sharp & Dohme and Ferring Pharmaceuticals. A.A. has received travel grants from Ferring Pharmaceuticals, Pfizer and a speaker honourarium from Sandoz Pharma Services.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 1.R.L. Cate, R.J. Mattaliano, C. Hession, R. Tizard, N.M. Farber, A. Cheung, E.G. Ninfa, A.Z. Frey, D.J. Gash, E.P. Chow, R.A. Fisher, J.M. Bertonis, G. Torres, B.P. Wallner, K.L. Ramachandran, R.C. Ragin, T.F. Manganaro, D.T. MacLaughlin, P.K. Donahoe, Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 45, 685–698 (1986)CrossRefGoogle Scholar
- 10.S. Halawaty, E. ElKattan, H. Azab, N. ElGhamry, H. Al-Inany, Effect of obesity on parameters of ovarian reserve in premenopausal women. J. Obstet. Gynaecol. 32, 687–690 (2010)Google Scholar
- 14.A.P. Ferraretti, A. La Marca, B.C.J.M. Fauser, B. Tarlatzis, G. Nargund, L. Gianarolion, on behalf of the ESHRE working group on Poor Ovarian Response Definition: ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human. Reprod. 26(7), 1616–1624 (2011)CrossRefGoogle Scholar
- 15.WHO. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. (World Health Organization, Geneva, 1995).Google Scholar
- 20.J. Simões-Pereira, J. Nunes, A. Aguiar, S. Sousa, C. Rodrigues, J. Sampaio Matias, C. Calhaz-Jorge, Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine (2018). https://doi.org/10.1007/s12020-018-1555-y.
- 22.S. Jung, N. Allen, A.A. Arslan, L. Baglietto, L.A. Brinton, B.L. Egleston, R. Falk, R.T. Fortner, K.J. Helzlsouer, A. Idahl, R. Kaaks, E. Lundin, M. Merritt, C. Onland-Moret, S. Rinaldi, M.J. Sanchez, S. Sieri, H. Schock, X.O. Shu, P.M. Sluss, P.N. Staats, R.C. Travis, A. Tjønneland, A. Trichopoulou, S. Tworoger, K. Visvanathan, V. Krogh, E. Weiderpass, Zeleniuch-Jacquotte, W. Zheng, J.F. Dorgan, Demographic, lifestyle, and other factors in relation to antimullerian hormone levels in mostly late premenopausal women. Fertil. Steril. 107, 1012–1022.e2 (2017)CrossRefGoogle Scholar
- 23.I.A. van Rooij, F.J. Broekmans, G.J. Scheffer, C.W. Looman, J.D. Habbema, F.H. de Jong, B.J. Fauser, A.P. Themmen, E.R. te Velde, Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil. Steril. 83, 979–987 (2005)CrossRefGoogle Scholar
- 24.Y. Fu, X. Zheng, L. Bao, K. Xu, X. Cheng, M. Sun, X. Xue, H. Chen, T. Yang, M. Zhang, Assessment of physiological factors for the establishment of serum insulin reference intervals in healthy Chinese Han adults: a community-based large cross-sectional study. Scand. J. Clin. Lab. Invest. 75, 319–326 (2015)CrossRefGoogle Scholar
- 30.Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, K. Hotta, I. Shimomura, T. Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. Okubo, K. Matsubara, M. Muraguchi, Y. Ohmoto, T. Funahashi, Y. Matsuzawa, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem. Biophys. Res. Commun. 425, 560–564 (2012)CrossRefGoogle Scholar